Cesca Therapeutics Sponsors First Symposium on Haploidentical Stem Cell Transplantation in India

RANCHO CORDOVA, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it is hosting the first annual Symposium on Haploidentical Stem Cell Transplantation in Delhi, India on January 7, 2016. The symposium will bring together National and International experts in the field of pediatrics and hematology/oncology to discuss current protocols and challenges for immune-oncology therapeutic approaches from a half-HLA matched (haploidentical),  related donor. The program will include panel discussions on the latest clinical data and the merits of this treatment option in the current health care scenario. Haploidentical transplantation is a treatment option gaining global acceptance as it increases the possibility and practicality of finding an acceptable donor match, known as an HLA (genotype) match. Parents are always a half-match for their children and siblings have at least a 75% chance of a match (full match and half match). Until recently, use of closely related donor sources such as the patient’s parents came with a high risk of potentially fatal Graft versus Host disease, where donor immune cells attack the recipient’s cells. New protocols that involve ex-vivo selection or removal of specific sub-types of T lymphocytes, a service provided in Cesca’s TotipotentRX cell processing laboratory in Delhi, India, are now providing a good therapeutic option for patients in need of a life-saving bone marrow transplant for treatment of leukemia and genetic blood disorders such as sickle cell anemia. Other protocols for haploidentical transplantation incorporate drugs that suppress the recipient’s immune system in-vivo to promote acceptance of the donor’s immune system.

Use of haploidentical transplantation will greatly increase the options for patients in need of bone marrow transplant, particularly in India where there is a great unmet need due to a lack of public bone marrow banks. Dr. Venkatesh Ponemone, Ph.D., Executive Director, Clinical affairs at TotipotentRX, India, stated “We are very pleased to sponsor this symposium and excited to have Dr. Rupert Handgretinger, Professor of Pediatrics at the Children's Hospital, University of Tubingen, Germany to share his clinical experience in treating children with various cancers using haploidentical stem cell transplantation. This symposium is a welcome platform to bring together leading hemato/oncology physicians to review and discuss standards of practice and emerging protocols for bone marrow transplantation. We are committed to supporting the practice of bone marrow transplantation and enhancing the ability of India to meet the growing need for this therapy.”

The one-day symposium will be held on January 7, 2016, in the Hotel Leela, Gurgaon, New Delhi, and is expected to be an annual event.

About Cesca Therapeutics Inc.

Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.  These include:

  • SurgWerks; proprietary stem cell therapy point-of-care kits for the treatment of vascular and orthopedic indications that integrate the following indication specific elements:
    • Cell harvesting
    • Cell processing and selection
    • Cell diagnostics
    • Cell delivery
  • CellWerksTM; an integrated system which includes a protocol, disposables and equipment for intra-laboratory use in treatment of oncological and hematological disorders.
  • The AutoXpress® (AXP); a proprietary automated device, along with companion sterile blood processing disposables, for the harvesting of stem cells from cord blood.
  • The MarrowXpress (MXP); a device and disposable system based on the AutoXpress platform for the isolation and concentration of stem cells from bone marrow. Self-powered and microprocessor-controlled, the MXP contains flow control and optical sensors and concentrates white blood cells from bone marrow to a user- defined volume in 40 minutes while retaining over 90% of mononuclear cells (MNCs).
  • The BioArchive® System; an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries, for cryopreservation and archiving of cord blood stem cell units for transplant.

Forward Looking Statement

The statements contained herein may include statements of future expectations and other forward looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Descriptions of other risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements. Cesca may, at its discretion, choose to publish on-going interim notifications, but as a general policy only makes announcements regarding material or significant information, such as filing of applications, approvals, initiation of studies, and conclusions.

CONTACT: Contact:
Cesca Therapeutics Inc.

Investor Contact: Kirin Smith, PCG Advisory Group
646-863-6519, or ir@cescatherapeutics.com

Media Contact: Sean Leous, PCG Advisory Group
646-863-8998 or sleous@pcgadvisory.com